130 related articles for article (PubMed ID: 3304785)
1. Control of diabetes through a subcutaneous peritoneal access device (SPAD) in patients with resistance to subcutaneously injected insulin.
Dandona P; Fonseca V; Fernando O; Menon RK; Weerakoon J; Kurtz A; Stephen R
Diabetes Res; 1987 May; 5(1):47-9. PubMed ID: 3304785
[TBL] [Abstract][Full Text] [Related]
2. Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
Beylot M; Khalfallah Y; Laville M; Sautot G; Dechaud H; Serusclat P; Berthezene F; Riou JP; Mornex R
Diabete Metab; 1987; 13(4):450-6. PubMed ID: 3315766
[TBL] [Abstract][Full Text] [Related]
3. Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid").
Campbell IW; Kritz H; Najemnik C; Hagmueller G; Irsigler K
Diabetes Res; 1984 Jul; 1(2):83-8. PubMed ID: 6442226
[TBL] [Abstract][Full Text] [Related]
4. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
5. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
[No Abstract] [Full Text] [Related]
6. Subcutaneous injection with an insulin pen. Insulin absorption and plasma concentrations of glucose and free insulin.
de Meijer PH; Lutterman JA
Neth J Med; 1990 Feb; 36(1-2):4-12. PubMed ID: 2179752
[TBL] [Abstract][Full Text] [Related]
7. In search of the subcutaneous-insulin-resistance syndrome.
Schade DS; Duckworth WC
N Engl J Med; 1986 Jul; 315(3):147-53. PubMed ID: 3523242
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous insulin substitution in insulin-dependent diabetes mellitus. Pharmacokinetic and pharmacodynamic studies.
Olsson PO
Acta Med Scand Suppl; 1987; 718():1-78. PubMed ID: 3321929
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of unstable diabetes with a portable insulin-infusion pump (author's transl)].
Talaulicar M; Willms B
Dtsch Med Wochenschr; 1982 Mar; 107(11):419-23. PubMed ID: 7037348
[TBL] [Abstract][Full Text] [Related]
10. Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic.
Dandona P; Mier A; Boag F; Chappell M; Beckett AG
Diabetes Res; 1985 Jul; 2(4):213-6. PubMed ID: 2417774
[TBL] [Abstract][Full Text] [Related]
11. Insulin therapy on the peritoneal route: effects on glucose control in experimental insulin dependent diabetes.
Fischer U; Fritze K; Freyse EJ
Exp Clin Endocrinol; 1990 Feb; 95(1):11-21. PubMed ID: 2185935
[TBL] [Abstract][Full Text] [Related]
12. Improved lipoprotein surface and core lipid composition following intraperitoneal insulin delivery in insulin-dependent diabetes mellitus.
Bagdade JD; Dunn FL
Diabetes Metab; 1996 Dec; 22(6):420-6. PubMed ID: 8985650
[TBL] [Abstract][Full Text] [Related]
13. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
[TBL] [Abstract][Full Text] [Related]
14. [Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin].
Petkova M; Khristov V; Tsanev A
Vutr Boles; 1990; 29(1):74-7. PubMed ID: 2204207
[TBL] [Abstract][Full Text] [Related]
15. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
[TBL] [Abstract][Full Text] [Related]
16. Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients.
Bak JF; Nielsen OH; Pedersen O; Beck-Nielsen H
Diabetes Res; 1987 Nov; 6(3):155-8. PubMed ID: 3325220
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficiency of insulin suppository formulations containing sodium salicylate or sodium cholate in insulin dependent diabetic patients.
Hosny EA; Al-Marzouki ZM; Metwally ME; Souaida MY; Alshaik AR
Boll Chim Farm; 2003 Oct; 142(8):361-6. PubMed ID: 15040468
[TBL] [Abstract][Full Text] [Related]
18. A comparison of premeal subcutaneous insulin infusion and injection in type I diabetic patients under continuous basal subcutaneous insulin delivery.
Navascués I; Kerner W; Pfeiffer EF
Life Support Syst; 1985; 3(3):263-7. PubMed ID: 3900596
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.
Berhe T; Postellon D; Wilson B; Stone R
Pediatrics; 2006 Jun; 117(6):2132-7. PubMed ID: 16740857
[TBL] [Abstract][Full Text] [Related]
20. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term.
Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
